Who are Klotho Neurosciences Inc's main suppliers?

Klotho Neurosciences Inc (KLTO) key suppliers include: GRML, GRMLW, RLS. View the full supplier network at chainsifter.com/chain/KLTO.

Who are Klotho Neurosciences Inc's major customers?

Klotho Neurosciences Inc (KLTO) key customers include: TELEOST-BIOPHARMACEUTIC-LLC, GRMLW, GRMLW, ASSOCIATES-LLC, AUSTRIA-CAPITAL-LLC and 12 more. View the full customer network at chainsifter.com/chain/KLTO.

What sector is Klotho Neurosciences Inc in?

Klotho Neurosciences Inc (KLTO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Klotho Neurosciences Inc Supplier List (KLTO): 3 Verified Suppliers

3Suppliers

17Customers

2Debt Items

15Related Chains

Source-Backed Evidence Depth

Klotho Neurosciences Inc (KLTO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

1Distinct source URLs

7High confidence

0.714Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Klotho Neurosciences Inc Suppliers

Ticker	Name	Confidence	Evidence
GRML	GRML	92%	Reciprocal relationship from GRML graph: On March 4, 2026, Klotho Neurosciences, Inc. (the 'Company') entered into an Agreement and Plan of Merger (the 'Merger Agreement') with Greenland Mines Corp.,…
GRMLW	GRMLW	92%	Reciprocal relationship from GRMLW graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from GRMLW graph: On March 4, 2026, Klotho Neurosciences, Inc. (the “Company”) entered into …
RLS	RLS	92%	Pursuant to the license, RLS will exclusively provide us with the API pursuant to a separate manufacturing and supply agreement that the parties executed on November 27, 2014.

Klotho Neurosciences Inc Customers

Ticker	Name	Confidence	Evidence
TELEOST-BIOPHARMACEUTIC-LLC	TELEOST-BIOPHARMACEUTIC-LLC	85%	adversely affect the reported values in the future. On an annual basis, the Company tests the long-lived and intangible assets for impairment based on the projected net present value of cash flows fo…
GRMLW	GRMLW	72%	Reciprocal relationship from GRMLW graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from GRMLW graph: Reciprocal relationship from KLTO graph: es or damages with respect to cla…
GRMLW	GRMLW	72%	es or damages with respect to claims we may experience, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against…
ASSOCIATES-LLC	ASSOCIATES-LLC	62%	he interests of the Company’s executives and the Company’s stockholders. In addition, Company believes that equity awards with a time-based vesting feature promote executive retention because this fe…
AUSTRIA-CAPITAL-LLC	AUSTRIA-CAPITAL-LLC	62%	. F- 20 M&A Agreement (Chardan) On October 19, 2022, the Company signed an M&A/Capital Markets Advisory Agreement with Chardan Capital Markets to advise and assist the Company in negotiating the term…
BCRG-GROUP	BCRG-GROUP	62%	he interests of the Company’s executives and the Company’s stockholders. In addition, Company believes that equity awards with a time-based vesting feature promote executive retention because this fe…
CHRS	Coherus Oncology, Inc.	62%	Reciprocal relationship from CHRS graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from CHRS g…
COHERUS-BIOSCIENCES-INC	COHERUS-BIOSCIENCES-INC	62%	efective. Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. If our product candidates are approved, they will be subject to ongoi…
DELAWARE-GENERAL-CORPORATION-LAW-THE-DELAWARE-GE	DELAWARE-GENERAL-CORPORATION-LAW-THE-DELAWARE-GE	62%	es or damages with respect to claims we may experience, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against…
GREENLAND-MINES-CORP	GREENLAND-MINES-CORP	62%	es or damages with respect to claims we may experience, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against…
HANWHA-CHEMICAL-CORPORATION	HANWHA-CHEMICAL-CORPORATION	62%	efective. Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. If our product candidates are approved, they will be subject to ongoi…
HOSPIRA-AMGEN-INC-PFIZER-INC-BOEHRINGER-INGELHEI	HOSPIRA-AMGEN-INC-PFIZER-INC-BOEHRINGER-INGELHEI	62%	efective. Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. If our product candidates are approved, they will be subject to ongoi…
HWH	HWH International Inc.	62%	Reciprocal relationship from HWH graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from HWH graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from HWH grap…
KLOTHO-NEUROSCIENCES-INC	KLOTHO-NEUROSCIENCES-INC	62%	es or damages with respect to claims we may experience, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against…
SANDOZ-HOSPIRA-INC	SANDOZ-HOSPIRA-INC	62%	efective. Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. If our product candidates are approved, they will be subject to ongoi…
SANDOZ-INTERNATIONAL-GMBH	SANDOZ-INTERNATIONAL-GMBH	62%	efective. Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. If our product candidates are approved, they will be subject to ongoi…
SPECIAL-PURPOSE-ACQUISITION-COMPANY	SPECIAL-PURPOSE-ACQUISITION-COMPANY	62%	. F- 20 M&A Agreement (Chardan) On October 19, 2022, the Company signed an M&A/Capital Markets Advisory Agreement with Chardan Capital Markets to advise and assist the Company in negotiating the term…

Klotho Neurosciences Inc Debt Obligations

Instrument	Description	Confidence	Evidence
KLTO-DEBT-10531	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
KLTO-DEBT-10530	Warrants outstanding: 130000	90%	xbrl warrant detail from xbrl 2025-12-31.

Klotho Neurosciences Inc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Klotho Neurosciences Inc.

Klotho Neurosciences Inc Ownership

Holder	Name	Confidence	Evidence
KLTO-OWNER-METEORA-CAPITAL-LLC	METEORA CAPITAL, LLC	90%	13F overlay lists METEORA CAPITAL, LLC as top holder; 26 tracked holders.

Klotho Neurosciences Inc Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CHRS	Coherus Oncology, Inc.	100.00	1	['customer']
HWH	HWH International Inc.	100.00	1	['customer']
GRML	Greenland Mines Ltd	100.00	1	['supplier']
CAH	Cardinal Health, Inc.	50.00	2
BMY	Bristol-Myers Squibb Company	50.00	2
BMYMP	Bristol-Myers Squibb Co	50.00	2
GILD	Gilead Sciences, Inc.	50.00	2
INTA	Intapp, Inc.	50.00	2
MCK	McKesson Corporation	50.00	2
AZN	AstraZeneca PLC	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
AMRX	Amneal Pharmaceuticals, Inc.	50.00	2
FMS	Fresenius Medical Care AG	50.00	2
MRK	Merck & Co., Inc.	50.00	2
GRMLW	Greenland Mines Ltd	38.88	1	['customer', 'supplier']

Klotho Neurosciences Inc Supply Chain